title: Interferon-alfa treatment of facial infantile haemangiomas: with emphasis on the sight-threatening varieties. A clinical series.
abstract: OBJECTIVE
  To report on the efficacy of systemic Interferon-alfa therapy in controlling the endothelial proliferation in expanding facial haemangiomas of infancy threatening the eye.
  
  
  METHODS
  The series comprised 9 subjects with facial haemangiomas of rapid growth within the first few months of life. All haemangiomas had relation to an eyelid and affected the visual access to the eye. At least three tumours were also intraorbital, and in one case the glottis was affected. Interferon-alfa was given subcutaneously in daily doses of 3 mio units/m2. Ophthalmic follow-up including ultrasound evaluation was done, initially with intervals of 4-8 weeks.
  
  
  RESULTS
  Interferon-alfa was given over 9-41 weeks (median duration 22 weeks) in cumulated doses of 63-287 million units. Progression was arrested in all and with a subsequent tumour regression considered accelerated as judged from earlier clinical giant haemangioma experience. A control series was not possible. One patient had systemic prednisone added over some weeks. Two infants reacted with a flu-like malaise. A premature infant developed a slight spastic diplegia.
  
  
  CONCLUSIONS
  In the 9 infants with growing ophthalmic haemangiomas we recorded a good response to systemic Interferon-alfa administered as daily doses by subcutaneous injection. In general the treatment appeared well tolerated. During clinical follow-up diagnostic ultrasound evaluation (the depth dimension) proved helpful; in particular there was a sparing effect on CT and MRI scans which require general anaesthesia.
authors.affiliation: The University Eye Clinics of Rigshospitalet and Glostrup County Hospital and the University Department of Paediatrics, Rigshospitalet, Copenhagen, Denmark.
authors.forename: H C
authors.initials: HC
authors.lastname: Fledelius
authors.forename: N
authors.initials: N
authors.lastname: Illum
authors.forename: H
authors.initials: H
authors.lastname: Jensen
authors.forename: J U
authors.initials: JU
authors.lastname: Prause
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005142:Eyelid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005153:Facial Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D009918:Orbital Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D011241:Prednisone